CA 125 Method: ECLIA, Roche (Serum (s))

Specimens:	500 µl Serum (s)
Preanalytics/Notes:	Patients receiving high doses of biotin (> 5 mg / day) should be sampled at least 8 hours after the last application, as high levels of biotin may interfere with the test system. Please note: results obtained using different methods and/or test manufacturers cannot be compared with one another. The course of tumor markers should always be assessed by the same test.
Method:	ECLIA
Dimension:	U/ml
Set-up:	Mon Tue Wed Thu Fri Sat Sun
Duration:	1 day
Indication/Significance:	Tumour marker in the case of a known ovarian carcinoma: Therapy monitoring, follow up and diagnosis of recurrence. Not suitable for screening!
Interpretation:	CA 125 is the marker of more… CA 125 is the marker of first choice for the diagnosis and therapy or follow up of ovarian carcinoma. The sensitivity stated is 82 - 96 %. It can be used as second choice marker for the pancreatic carcinoma. The antigen defined by a monoclonal antibody, however, is neither specific for these tumours nor for malignant diseases. Elevated values can also be found with other, especially gynaecological and gastro-intestinal carcinomas (e.g. colorectal carcinoma 20 - 39 %, cervix carcinoma 13 - 54 %). The biological half-life is 5 - 10 days. see table under keyword "tumour marker" close
Further tests:	CEA, CA 15-3

performance by Bioscientia medical service centers

both sex
	< 35 U/ml